Cardiolife tablets coated

Nchi: Armenia

Lugha: Kiingereza

Chanzo: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Viambatanisho vya kazi:

acetylsalicylic acid, magnesium hydroxide

Inapatikana kutoka:

Arpimed LLC

ATC kanuni:

B01AC30

INN (Jina la Kimataifa):

acetylsalicylic acid, magnesium hydroxide

Kipimo:

75mg+ 15,2mg

Dawa fomu:

tablets coated

Vitengo katika mfuko:

(96/4x24/) in blister

Dawa ya aina:

OTC

Idhini hali ya:

Registered

Idhini ya tarehe:

2015-12-17

Tabia za bidhaa

SUMMARY PRODUCT CHARACTERISTIC (SPC) CARDIOLIFE
COATED TABLETS
1.1 TRADE NAME – Cardiolife
1.2
COMBINATION
OF
WELL-KNOWN
GENERICS
–
Acetylsalicylic
acid
/
Magnesium
hydroxide
2. COMPOSITION
Each tablet_ _contains:
_ACTIVE INGREDIENTS: _Acetylsalicylic acid – 75 mg, Magnesium
hydroxide – 15.2 mg;
_For a full list of excipients, see section 6.1. _
3. PHARMACEUTICAL FORM
White heart-shaped coated tablets
4.CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
•
Primary prevention of cardiovascular diseases such as thrombosis and
acute heart failure in the
presence of risk factors (eg, diabetes, hyperlipidemia, hypertension,
obesity, smoking, old age);
•
Prevention of recurrent myocardial infarction and thrombosis of blood
vessels;
•
Prevention of thromboembolic events after vascular surgery (coronary
artery bypass grafting,
percutaneous transluminal coronary angioplasty);
•
Unstable angina.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
The tablets should be swallowed whole with water.
_For primary prevention of cardiovascular diseases such as thrombosis
and acute heart failure in the _
_presence of risk factors (eg, diabetes, hyperlipidemia, hypertension,
obesity, smoking, older age)_
appoint 2 tablets of Cardiolife containing acetylsalicylic acid at a
dose of 75 mg the first day, followed
by 1 tablet of Cardiolife 1 time / day.
_For the prevention of repeated myocardial infarction and thrombosis
of blood vessels_ appoint
Cardiolife at a dose of 75-150 mg 1 time / day.
_For the prevention of thromboembolic events after vascular surgery
(coronary artery bypass grafting, _
_percutaneous transluminal coronary angioplasty)_ appoint Cardiolife
at a dose of 75-150 mg 1 time /
day.
_In unstable angina_ appoint Cardiolife at a dose of 75-150 mg 1 time
/ day. 4.3 CONTRAINDICATIONS
•
Bleeding in the brain;
•
Tendency to bleeding (vitamin K deficiency, thrombocytopenia,
hemorrhagic diathesis);
•
Asthma induced by intake of salicylates and NSAIDs;
•
Erosive and ulcerative lesions GIT (exacerbation);
•
Gastro-in